Medical Facilities (DR) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
14 May, 2026Business overview
Owns two highly rated specialty surgical hospitals in the US, focusing on short-duration, non-emergency procedures, with orthopedic and neurosurgical cases as the majority.
Operates in partnership with 67 physician partners, emphasizing direct physician involvement for operational efficiency.
Hospitals are Arkansas Surgical Hospital and Sioux Falls Specialty Hospital.
Financial performance
2025 revenue and other income reached US $254.2 million, with income from operations at US $46.7 million and EBITDA at US $58.4 million.
Q1 2026 facility service revenue grew 10.8% year-over-year to US $67.1 million.
Q1 2026 EBITDA increased 12.7% to US $15.3 million, with EBITDA margin at 22.8%.
Cash available for distribution in Q1 2026 was C$6.8 million, with a payout ratio of 23.1%.
Capital management and shareholder returns
Repurchased 439,400 shares for US $5.4 million in 2026 YTD and 5,155,113 shares for US $63.7 million in 2025.
Since September 2022, 11,973,110 shares bought back for US $121.5 million.
1,255,924 shares remain available for repurchase under the current NCIB, expiring November 2026.
Latest events from Medical Facilities
- Revenue up 10.8%, EBITDA up 13.8%, and cash boosted by $46M asset sale.DR
Q1 20267 May 2026 - Delivers strong financials and shareholder returns through high-quality specialty surgical hospitals.DR
Investor presentation10 Apr 2026 - Strong revenue and earnings growth, major asset sales, and buybacks boosted shareholder returns.DR
Q4 202512 Mar 2026 - Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 20242 Feb 2026 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 202416 Jan 2026 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 202426 Dec 2025 - Revenue and EBITDA stable, net income up, and $44.3M returned to shareholders via buybacks.DR
Q1 202525 Nov 2025 - Q2 saw SFSH headwinds but strong net income growth and new $40M credit secured.DR
Q2 202523 Nov 2025 - 7.5% revenue growth, 10.2% higher EBITDA, and $5.6M in share buybacks in Q3 2025.DR
Q3 202513 Nov 2025